Quick Answer
Palomino Laboratories Inc. reported Cash and Equivalents of $8.12 million for fiscal year 2025.
Palomino Laboratories Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.12M | +5931.2% |
| 2024 | $134.7K | +35336.1% |
| 2023 | $380.00 | -24.0% |
| 2022 | $500.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.90M | — | +5764.2% |
| December 31, 2024 | $134.7K | +35336.1% | +35336.1% |
| March 31, 2024 | $380.00 | — | +0.0% |
| December 31, 2023 | $380.00 | -24.0% | +0.0% |
| September 30, 2023 | $380.00 | — | -24.0% |
| December 31, 2022 | $500.00 | — | — |
- Palomino Laboratories Inc. showed an increase of +5931.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Palomino Laboratories Inc.’s cash and equivalents has grown by 1624189.0% (from $500.00 to $8.12 million).
- The most recent figure is from Palomino Laboratories Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: